KOBIO, the First Web-based Korean Biologics Registry Operated With a Unified Platform Among Distinct Disease Entities
10.4078/jrd.2021.28.4.176
- Author:
Jinhyun KIM
1
;
Jung Hee KOH
;
Sung Jae CHOI
;
Chan Hong JEON
;
Seung-Ki KWOK
;
Seong-Kyu KIM
;
Chan-Bum CHOI
;
Jaejoon LEE
;
Changhoon LEE
;
Eon Jeong NAM
;
Yong-Beom PARK
;
Shin-Seok LEE
;
Tae-Hwan KIM
;
Sung-Hwan PARK
;
Jung-Yoon CHOE
;
Eun-Mi KOH
;
Dae-Hyun YOO
;
Yeong Wook SONG
;
Hyoun-Ah KIM
;
Kichul SHIN
Author Information
1. Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea
- Publication Type:Review Article
- From:Journal of Rheumatic Diseases
2021;28(4):176-182
- CountryRepublic of Korea
- Language:English
-
Abstract:
The KOrean College of Rheumatology BIOlogics and targeted therapy (KOBIO) registry is a nationwide observational cohort that captures detailed data on exposure of patients to biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). This registry was launched in December 2012 with an aim to prospectively investigate clinical manifestations and outcomes of patients with rheumatoid arthritis (RA), ankylosing spondylitis, and psoriatic arthritis who initiated a biologic or targeted synthetic DMARD or switched to another. Demographic data, disease activity, current treatment, adverse events, terms based on Medical Dictionary for Regulatory Activities, and so on are registered for patients who are then followed up annually in a web-based unified platform. The KOBIO registry also recruits and collects data of patients with RA on conventional DMARDs for comparison. As of today, more than 5,500 patients were enrolled from 47 academic and community Rheumatology centers across Korea. The KOBIO registry has evolved to become a powerful database for clinical research to improve clinical outcomes and quality of treatment.
